Could a common drug slow Alzheimer's? new study recruits volunteers
NCT ID NCT04629495
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 22 times
Summary
This study tests whether rapamycin, a drug used for other conditions, is safe and tolerable for older adults with mild cognitive impairment or early Alzheimer's disease. Over 12 months, 40 participants will take oral rapamycin and be monitored for side effects, changes in memory, and drug levels in the brain. The goal is to see if this approach can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.